TheraRadar
← Back
Data updated: Jun 28, 2026

ALEXION PHARM

Biotech
ImmunologyInfectious DiseaseCardiovascular Execution: Fair

ALEXION PHARM is a biotechnology company focused on Immunology, Infectious Disease, Cardiovascular. Key products include STRENSIQ.

2007
Since
4
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
3 Biologics

FDA Novel Drug Designations

(2018)
1 Novel 1 Orphan
See 1 novel approval →
2018 ULTOMIRIS (RAVULIZUMAB-CWVZ) Orphan

ALEXION PHARM at a Glance

  • Fast trial execution (20 months median completion)

ALEXION PHARM's Key Drugs

ALEXION PHARM's core commercial portfolio centers on ULTOMIRIS, STRENSIQ, KANUMA, spanning Immunology and Infectious Disease — its most strategically important drugs approved in the last 15 years.

ULTOMIRIS
Immunology

Paroxysmal nocturnal hemoglobinuria (PNH)

C5 Approved 2018
STRENSIQ
Rare Disease

Hypophosphatasia

TNSALP Approved 2015
KANUMA
Rare Disease

Lysosomal Acid Lipase Deficiency

Lysosomal acid lipase Approved 2015

ALEXION PHARM's Recent FDA Approvals

New NDA/BLA approvals for ALEXION PHARM over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

ALEXION PHARM's Therapeutic Areas

ALEXION PHARM's approved drugs and pipeline span 5 therapeutic areas, led by Immunology and Infectious Disease, across 3 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Immunology 28%
0 drugs Phase 2: 5 Phase 1: 1
Infectious Disease 28%
0 drugs Phase 3: 1 Phase 2: 3 Phase 1: 1
Cardiovascular 21%
0 drugs Phase 3: 1 Phase 2: 1 Phase 1: 2
Metabolic 13%
0 drugs Phase 3: 1 Phase 1: 1
Respiratory 10%
0 drugs Phase 3: 1

ALEXION PHARM Pipeline Snapshot

ALEXION PHARM has 18 active clinical programs from ClinicalTrials.gov — 4 Phase 3, 9 Phase 2 and 5 Phase 1.

4
Phase 3
9
Phase 2
5
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • ULTOMIRIS leads revenue
  • • 3 key drugs tracked
View revenue breakdown →

Trial Catalysts

  • • Immunology pipeline focus
  • • Phase 3 readout tracking
View full pipeline →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis
View patent timeline →

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Compare with competitor →

Execution Intelligence

  • • Phase 3: 23/47 completed
  • • Speed: 20 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges